RL, Stump J. Life-threatening interaction of mibefradil and beta

Document technical information

Format doc
Size 12.5 kB
First found May 22, 2018

Document content analysis

Category Also themed
Language
Type
not defined
Concepts
no text concepts found

Persons

Organizations

Places

Transcript

RL, Stump J. Life-threatening interaction of mibefradil
and beta-blockers with dihydropyridine calcium channel
b\octers.JAAfA 1998;280;157-158.
341.Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson
PE, Belkin RN, Miller AB, Neuberg GW, Frid D,
Wertheimer JH, Cropp AB, DeMets DL, for the Prospective
Randomized Amlodipine Survival Evaluation Study
Group. Effect of amlodipine on morbidity and mortality in
severe chronic heart failure. N EnglJMed 1996;335:1107-1114.
342.Cohn JN, Ziesches S, Smith R, Anand I, Dunkman WB,
Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss
L, for the Vasodilator-Heart Failure Trial (V-HeFT) Study
Group. Effect of the calcium antagonist felodipine as
supple-mentary vasodilator therapy in patients with
chronic heart failure treated with enalapril:V-Heft III.
Circulation 197;96:856-863.
343.Levine TB for the MACH-1 Investigators. The design of
the Mortality Assesment in Congestive Heart Failure Trial
(MACH-1,mibefradil). Clin Cardiol 1997;20:320-326.
344.Elkayam U.Presention of theMACH-1 Trial.XXI
Congress of the European Society of Cardiology, 25
August, 1998.
345.Po AL, Zhang WY. What lessons can be learnt from
withdrawal of mibefradil from the market. Lancet
1998;35:1829-1830.
346.Billups SJ, Carter BL. Mibefradil withdrawn from the
market. Ann Pharmacother 1998;32:841.Letter.
347.Packer M. Sudden Unexpected death in patients with
congestive heart failure: a second frontier. Circulation
1985;72:681-685.
348.Kjekshus J. Arrhythmias and morality in congestive heart
failure. Am J Cardiol 1990;65:4231-481.
349.The Cardiac Arrhythmia Suppression Trial (CAST)
Investigators. Preliminary report: effect of encainide and
flecainide on mortality in a randomized trial of arrhytmia
suppression after myocardial infarction. N Engl J Med
1989;321:406-412.
350.The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on
survival after myocardial infarction. N Engl J Med
1992;327:227-233.
351.Gottlieb SS, Kukkin ML, Medina N, Yushak M, Packer
M. Comparative hemodynamic effects of procainamide,
tocainide and encainide in severe chronic heart failure.
Circulation 1990;81:860-864.
352.Packer M. Hemodynamic consequences of antiarrhythmic
drug therapy in patients with chronic heart failure . J
Cardiovasc Electrophysiol 1991 ;2(suppl):S240-S247.
353.Coplen SE, Antman EM, Berlin JA, Hewit P, Chalmers
TC. efficacy and safety of quinidine therapy for maintenance
of sinus rhythm after cardioversion:A meta-analysis of
randomized control trials. Circulation 1990;82:1106-1116.
354.Hansteen V, Moinichen E, Lorentsen E, Andersen A,
Strom O, Soiland K, Dyrbekk D, Refsum AM, Tromsdal
A, Knudsen K, Eika C, Bakken J Jr, Smith P, Hoff PL One
year's treatment with propranolol after myocardial
infarction preliminary report of Norwegian multicentre
trial. JSM/1982;284:155-160.
355.Du XJ, Esler MD, Dart AM. Sympatholytic action of
intravenous amiodarone in the rat heart. Circulation
1995 ;91:462-470.
356.Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman
GR, Curiel R, for Grupo de Estudio de la Sobrevida en la
Insuficiencia Cardiaca en Argentina (GESICA). Randomised
trial of low-dose amiodarone in severe congestive heart failure.
Lancet 1994;344:463-498. 357.Singh SN, Fletcher RD, Fisher
SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling
C, Lazzeri D, for the Survival Trial of Antiarrhythmic
Therapy in Cingestive Heart Failure. Adiodarone in patients
with congestive heart failure and asymptomatic ventricular
arrhythmias. N EnglJMed 1995;333:77-82.
358.Massie BM, Fisher SG, Radford M, Deedwania PC, Singh
BN, Fletcher RD, Singh SN. Effect of amiodarone on
clinical status and left ventricular function in patients with
congestive heart failure. CHF-STAT Investigators.
Circulation 1996;93:2128-2134.
359.Naccarelli GV, Rinkenberger RL, Dougherty AH,
Fitzgerald DM. Adverse effects of amiodarone. Med
Toxicol Adverse Drug Exp 1989;4:246-253.
360.Greene BW, Graham EL, Werner JA, Sears GK, Gross
BW, Gorham JP, Kudenchuk PJ, Trobaugh GB. Toxic and
therapeutic effects of amiodarone in the treatment of
cardiac arrhythmias. J Am Coll Cardiol 1983;2:1114-1128.
361.Waldo AL, Camm AJ, DeRuyter H, Friedman PL,
MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri
EP, for the SWORD Investigators. Effect of rf-sotalol on
mortality in patients with left ventricular dysfunction after
recent and remote myocardial infarction. Lancet 1996;
348:7-12.
362 Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled
trial of sotalol for one year after myocardial infarction.
Lancet 1982;1:1142-1147.
363.Danish Investigations on Arrhythmia and Mortality ON
Dofetilide. Dofetilide in patients with left ventricular
dysfunction and either heart failure or acute myocardial
infarction: rationale, design, and patient characteristics of
the DIAMOND studies. Clin Cardiol 1997;20:704-710.
634.Torp-Pedersen for the Danish Investigations of Arrhythmia
and Mortality on Dofetilide (DIAMOND) Study Group.
Dofetilide: a new clss III antiarrhythmic drug which is safe in
patients with congestive heart failure. (Abstr.)/ Am Coll
Cardiol 1998;31;160A
365.Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenberg
RO, frye RL. The natural history of idiopathic dilated
cardiomyopathy./1m/Cord/0/1981;47:5 25-531.
366.Stratton JR, Nemanich JW, Johannessen KA, Resnick AD.
Fate of left ventricular thrombi in patients with remote
myocardial infarction or idiopathic cardiomyopathy.
Circulation 1988;78:1388-1393.
367.Jafri SM. Hypercoagulability in heart failure. Semin
Thromb Hemost 1997;23:543-545.
368.Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell
L, Cohn JN for the V-HeFT VA Cooperative Studies
Group. Incidence of thromboembolic events in congestive
heart failure. Circulation 1993;87(suppl VI):94-101.
369.Dunkman WB. Thromboembolism and antithrombotic
therapy in congestive heart failure. J Cardiovasc Risk
1995;2:107-117.
370.Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C,
Cobelli F, Tavazzi L. Systemic thromboembilism in chronic
heart failure. A prospective study in 406 patients. Eur Heart
/1996;17:1381-1389.
371.Baker DW, Wright RF. Management of heart failure. IV.
Anticoagulation for patients with heart failure due to left

Similar documents

×

Report this document